Gummersbach

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

This research aims to observe the long-term safety of efgartigimod treatment in adults with generalized myasthenia gravis gMG. It compares patients who are starting or have recently started efgartigimod treatment with those who have not been exposed to efgartigimod and are receiving other standard treatments. The study is non-interventional and prospective, focusing on real-world safety outcomes over an extended period. Participants are divided into two groups one receiving efgartigimod and another receiving other medications for myasthenia gravis. This study does not involve any new treatments being administered as part of the trial but monitors patients during their routine care. The study will continue for up to 10 years to gather long-term safety data. During the study, researchers will track the occurrence of serious infections and other safety concerns in both groups. Patients will be monitored through their regular clinical visits without additional interventions from the study. Participants may be followed for up to 10 years to assess safety outcomes associated with their treatments in everyday medical practice.

Researchers are evaluating the efficacy, safety, and tolerability of remibrutinib compared to a placebo in adult patients with Generalized Myasthenia Gravis gMG who are already on stable standard-of-care treatments. This multicenter Phase III study is randomized, double-blind, and placebo-controlled, aiming to provide important information about remibrutinibs impact on gMG symptoms. Participants will be randomly assigned to one of two groups one receiving remibrutinib tablets orally, and the other receiving matching placebo tablets, both during a 6-month core treatment period. Following this, participants can join an extension phase lasting up to 60 months, where all will receive open-label remibrutinib tablets orally. During the study, participants will undergo various assessments to monitor their symptoms and quality of life, including the Myasthenia Gravis Activity of Daily Living MG-ADL score and other clinical scales. Safety and tolerability will also be closely observed throughout the core and extension periods. The total duration of participation may extend up to nearly six years, including both study phases.